Abstract
Using single and double transgenic mouse models, we investigated how c-Myc modulates the mammary epithelial cell cycle to induce cancer and how TGFα enhanced the process. In c-myc transgenic mice, c-myc expression was high in the hyperplastic mammary epithelium and in the majority of tumor areas. However, the tumors displayed focal areas of low expression of c-myc but high rates of proliferation. In contrast to E2F1 and cyclin A2, which were induced and co-localized with c-myc expression, induction of cyclins D1 and E occurred only in these tumor foci. Overexpression of cyclin D1 also occurred in the hyperplastic epithelium of tgfα-single and tgfα/c-myc-double transgenic mice. In tgfα/c-myc tumors, cells positive for cyclins D1 and E were randomly spread, without showing a reciprocal relationship to c-myc expression. In contrast to c-myc tumors, most tgfα/c-myc tumors showed undetectable levels of retinoblastoma protein (pRB), and the loss of pRB occurred in some cases at the mRNA level. These results suggest that E2F1 and cyclin A2 may be induced by c-Myc to mediate the onset of mammary cancer, whereas overexpression of cyclins D1 and E may occur later to facilitate tumor progression. TGFα may play its synergistic role, at least in part, by inducing cyclin D1 and facilitating the loss of pRB.
Similar content being viewed by others
Abbreviations
- Cdk:
-
cyclin-dependent kinase
- ER:
-
estrogen receptor
- MMTV:
-
mouse mammary tumor virus
- MT:
-
metallathionein
- PCNA:
-
proliferating cell nuclear antigen
- pRB:
-
retinoblastoma protein
- TGFα:
-
transforming growth factor α
- TUNEL:
-
terminal deoxynucleotidyl transferase nick end labeling
References
Alexandrow MG and Moses HL . 1998 J Cell Biochem 70: 528–542
Amati B, Alevizopoulos K and Vlach J . 1998 Front Biosci 3: D250–D268
Amundadottir LT, Johnson MD, Merlino G, Smith GH and Dickson RB . 1995 Cell Growth Differ 6: 737–748
Amundadottir LT, Merlino G and Dickson RB . 1996a Breast Cancer Res Treat 39: 119–135
Amundadottir LT, Nass SJ, Berchem GJ, Johnson MD and Dickson RB . 1996b Oncogene 13: 757–765
Auvinen PK, Lipponen PK, Kataja VV, Johansson RT and Syrjanen KJ . 1996 Acta Oncol 35: 995–998
Barnes DM and Gillett CE . 1998 Breast Cancer Res Treat 52: 1–15
Bernards R, Schackleford GM, Gerber MR, Horowitz JM, Friend SH, Schartl M, Bogenmann E, Rapaport JM, McGee T and Dryja TP . 1989 Proc Natl Acad Sci USA 86: 6474–6478
Bodrug SE, Warner BJ, Bath ML, Lindeman GJ, Harris AW and Adams JM . 1994 EMBO J 13: 2124–2130
Cardiff RD and Munn RJ . 1995 Cancer Lett 90: 13–19
Cole MD and McMahon SB . 1999 Oncogene 18: 2916–2924
Daksis JI, Lu RY, Facchini LM, Marhin WW and Penn LJ . 1994 Oncogene 9: 3635–3645
Dang CV . 1999 Mol Cell Biol 19: 1–11
Desdouets C, Sobczak-Thepot J, Murphy M and Brechot C . 1995 Prog Cell Cycle Res 1: 115–123
Dickson RB and Lippman ME . 1995 Endocr Rev 16: 559–589
Eldrige SR, Butterworth BE and Goldsworthy TL . 1993 Environ Health Perspect 101: Suppl 5, 211–218
Ezhevsky SA, Nagahara H, Vocero-Akbani AM, Gius DR, Wei MC and Dowdy SF . 1997 Proc Natl Acad Sci USA 94: 10699–10704
Facchini LM and Penn LZ . 1998 FASEB J 12: 633–651
Gray-Bablin J, Zalvide J, Fox MP, Knickerbocker CJ, DeCaprio JA and Keyomarsi K . 1996 Proc Natl Acad Sci USA 93: 15215–15220
Gu Y, Rosenblatt J and Morgan DO . 1992 EMBO J 11: 3995–4005
Han EK, Sgambato A, Jiang W, Zhang YJ, Santella RM, Doki Y, Cacace AM, Schieren I and Weinstein IB . 1995 Oncogene 10: 953–961
Jansen-Durr P, Meichle A, Steiner P, Pagano M, Finke K, Botz J, Wessbecher J, Draetta G and Eilers M . 1993 Proc Natl Acad Sci USA 90: 3685–3689
Jhappan C, Stahle C, Harkins RN, Fausto N, Smith GH and Merlino GT . 1990 Cell 61: 1137–1146
Johnson DG and Schneider-Broussard R . 1998 Front Biosci 3: d447–d448
Kerkhoff E, Houben R, Loffler S, Troppmair J, Lee JE and Rapp UR . 1998 Oncogene 16: 211–216
Keyomarsi K, O'Leary N, Molnar G, Lees E, Fingert HJ and Pardee AB . 1994 Cancer Res 54: 380–385
Keyomarsi K and Pardee AB . 1993 Proc Natl Acad Sci USA 90: 1112–1116
Kotani S, Endo T, Kitagawa M, Higashi H and Onaya T . 1995 Oncogene 10: 663–669
Kwon TK, Buchholz MA, Jun DY, Kim YH and Nordin AA . 1998 Exp Cell Res 238: 128–135
Land H, Parada LF and Weinberg RA . 1983 Nature 304: 596–602
Lavia P and Jansen-Durr P . 1999 Bioessays 21: 221–230
Lee DC, Fenton SE, Berkowitz EA and Hissong MA . 1995 Pharmacol Rev 47: 51–85
Leone G, DeGregori J, Sears R, Jakoi L and Nevins JR . 1997 Nature 387: 422–426
Li JJ, Hou X, Banerjee SK, Liao DZ, Maggouta F, Norris JS and Li SA . 1999 Cancer Res 59: 2340–2346
Li Y, Slansky JE, Myers DJ, Drinkwater NR, Kaelin WG and Farnham PJ . 1994 Mol Cell Biol 14: 1861–1869
Liao DZ, Pantazis CG, Hou X and Li SA . 1998 Carcinogenesis 9: 2173–2180
Lukas J, Bartkova J and Bartek J . 1996 Mol Cell Biol 16: 6917–6925
Lykkesfeldt AE . 1996 Acta Oncol 35 Suppl 5: 9–14
Marhin WW, Hei YJ, Chen S, Jiang Z, Gallie BL, Phillips RA and Penn LZ . 1996 Oncogene 12: 43–52
Matsui Y, Halter SA, Holt JT, Hogan BL and Coffey RJ . 1990 Cell 61: 1147–1155
Morgan DO . 1995 Nature 374: 131–134
Nass SJ and Dickson RB . 1997 Breast Cancer Res Treat 44: 1–22
Neuman E, Ladha MH, Lin N, Upton TM, Miller SJ, DiRenzo J, Pestell RG, Hinds PW, Dowdy SF, Brown M and Ewen ME . 1997 Mol Cell Biol 17: 5338–5347
Nielsen NH, Arnerlov C, Emdin SO and Landberg G . 1996 Br J Cancer 74: 874–880
Noguchi E, Sekiguchi T, Yamashita K and Nishimoto T . 1993 Biochem Biophys Res Commun 197: 1524–1529
Obaya AJ, Mateyak MK and Sedivy JM . 1999 Oncogene 18: 2934–2941
Panico L, D'Antonio A, Salvatore G, Mezza E, Tortora G, De Laurentiis M, De Placido S, Giordano T, Merino M, Salomon DS, Mullick WJ, Pettinato G, Schnitt SJ, Bianco AR and Ciardiello F . 1996 Int J Cancer 65: 51–56
Philipp A, Schneider A, Vasrik I, Finke K, Xiong Y, Beach D, Alitalo K and Eilers M . 1994 Mol Cell Biol 14: 4032–4043
Pilichowska M, Kimura N, Fujiwara H and Nagura H . 1997 Mod Pathol 10: 969–975
Planas-Silva MD and Weinberg RA . 1997 Mol Cell Biol 17: 4059–4069
Prall OW, Rogan EM, Musgrove EA, Watts CK and Sutherland RL . 1998 Mol Cell Biol 18: 4498–4508
Quelle DE, Ashmun RA, Shurtleff SA, Kato JY, Bar-Sagi D, Roussel MF and Sherr CJ . 1993 Genes Dev 7: 1559–1571
Roussel MF . 1998 Adv Cancer Res 74: 1–24
Sabath DE, Broome HE and Prystowsky MB . 1990 Gene 91: 185–191
Said TK and Medina D . 1995 Carcinogenesis 16: 823–830
Sandgren EP, Luetteke NC, Palmiter RD, Brinster RL and Lee DC . 1990 Cell 61: 1121–1135
Santoni-Rugiu E, Jensen MR and Thorgeirsson SS . 1998 Cancer Res 58: 123–134
Schmidt EV . 1999 Oncogene 18: 2988–2996
Sears R, Leone G, DeGregori J and Nevins JR . 1999 Mol Cell 3: 169–179
Seshadri R, Lee CS, Hui R, McCaul K, Horsfall DJ and Sutherland RL . 1996 Clin Cancer Res 2: 1177–1184
Sgambato A, Han EK, Zhou P, Schieren I and Weinstein IB . 1996 Cancer Res 56: 1389–1399
Sherr CJ . 1996 Science 274: 1672–1677
Sinn E, Muller W, Pattengale P, Tepler I, Wallace R and Leder P . 1987 Cell 49: 465–475
Solomon DL, Philipp A, Land H and Eilers M . 1995 Oncogene 11: 1893–1897
Steeg PS and Zhou Q . 1998 Breast Cancer Res Treat 52: 17–28
Stewart TA, Pattengale PK and Leder P . 1984 Cell 38: 627–637
Sweeney C, Murphy M, Kubelka M, Ravnik SE, Hawkins CF, Wolgemuth DJ and Carrington M . 1996 Development 122: 53–64
Valverius EM, Ciardiello F, Heldin NE, Blondel B, Merlo G, Smith G, Stampfer MR, Lippman ME, Dickson RB and Salomon DS . 1990 J Cell Physiol 145: 207–216
Wilcken NR, Prall OW, Musgrove EA and Sutherland RL . 1997 Clin Cancer Res 3: 849–854
Yang R, Morosetti R and Koeffler HP . 1997 Cancer Res 57: 913–920
Acknowledgements
We would like to express sincere gratitude to Dr W-H Lee, Department of Molecular Medicine and Institute of Biotechnology, University of Texas Health Science Center, San Antonio, TX, USA, for generously providing the antibody pRB245, to Mrs S Constable for helping in tissue processing, and to Dr E Rosfjord, J-K Wang, and Dr M-Z Dai for helping in preparing digital photos. This work was supported by NIH grants RO1 CA72460 and AG1496 to RB Dickson.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Liao, D., Natarajan, G., Deming, S. et al. Cell cycle basis for the onset and progression of c-Myc-induced, TGFα-enhanced mouse mammary gland carcinogenesis. Oncogene 19, 1307–1317 (2000). https://doi.org/10.1038/sj.onc.1203430
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1203430
- Springer Nature Limited
Keywords
This article is cited by
-
Integrated whole transcriptome profiling revealed a convoluted circular RNA-based competing endogenous RNAs regulatory network in colorectal cancer
Scientific Reports (2024)
-
Silencing or inhibition of H3K79 methyltransferase DOT1L induces cell cycle arrest by epigenetically modulating c-Myc expression in colorectal cancer
Clinical Epigenetics (2019)
-
Challenges and advances in mouse modeling for human pancreatic tumorigenesis and metastasis
Cancer and Metastasis Reviews (2013)
-
Leptin-induced growth of human ZR-75-1 breast cancer cells is associated with up-regulation of cyclin D1 and c-Myc and down-regulation of tumor suppressor p53 and p21WAF1/CIP1
Breast Cancer Research and Treatment (2006)
-
Correlation of amplification and overexpression of the c-myc oncogene in high-grade breast cancer: FISH, in situ hybridisation and immunohistochemical analyses
British Journal of Cancer (2004)